COLUMBIA, Md., March 14, 2012 /PRNewswire/ -- The PML Consortium, an association of pharmaceutical and biotechnology companies, has recently selected the Labmatrix and Qiagram software environments from BioFortis to share and manage data relating to biospecimens in a collaborative effort to study a serious adverse event.
Progressive multifocal leukoencephalopathy (PML) is an often-fatal disease caused by the JC virus in immunocompromised patients. PML has been identified as a known side effect to certain immunosuppressive drugs. Several pharmaceutical and biotechnology companies have established the PML Consortium in order to pool study resources together, so they can derive insights that otherwise might not be gained from separate, individual studies. Current members of the PML Consortium include Biogen Idec, Bristol-Myers Squibb, Elan, Pfizer, and Roche.
Through the web-accessible Labmatrix and Qiagram collaborative software environments, global PML Consortium members can 1). centrally manage de-identified or anonymized patient clinical profiles and biospecimen information in the virtual sample bank, 2). explore available biospecimens in the virtual sample bank and related data using complex, ad hoc criteria, 3). request, approve, and track transfers of biospecimens in the virtual sample bank, and 4). log user interactions and virtual sample bank inventory history for usage transparency, information security, and accountability.
"This application will enable us to store clinical data and sample data collected by the Consortium, and enable research to be carried out in an innovative collaborative effort and thorough scientific approach into PML and its causes," states Sophie Banzet, M.D., Chair of the PML Consortium Board of Directors.
"With the complementary capabilities of a transactional database for managing daily scientific operations, and a graphical data exploration engine for posing complex questions," state
|SOURCE BioFortis, Inc.|
Copyright©2010 PR Newswire.
All rights reserved